Monday, October 14, 2019
News
NEWS HOME
»
PRN INDIA
A New Approach to Treating Alzheimer's Disease Receives Major NIA Backing
  SocialTwist Tell-a-Friend  
   

T3D Therapeutics to Receive $9 Million Multiyear National Institute on Aging Grant for Phase 2 PIONEER Study in Mild-to-Moderate Alzheimer's Disease Patients

RESEARCH TRIANGLE PARK, North Carolina, May 20, 2019 /PRNewswire/ --  T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959 (the "Company"), a new orally administered treatment for Alzheimer's disease (AD), announced today that it has received a grant expected to total $9 million dollars over four years from the National Institute on Aging (NIA), part of NIH, to help fund a Phase 2 clinical study of T3D-959, a novel, metabolic-focused AD drug treatment.

The Phase 2 PIONEER study (Prospective therapy to Inhibit and Overcome Alzheimer's Disease Neurodegeneration via Brain EnErgetics and Metabolism Restoration) is expected to initiate patient dosing in early 2020. PIONEER is a  double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study expected to enroll up to 252 adults with mild-to-moderate Alzheimer's disease (MMSE 16-26). PIONEER will enroll subjects who will receive one of three different doses of T3D-959 or a placebo for 24 weeks.

"We see this grant award as recognition that improving inherent metabolic defects in Alzheimer's disease is a vital and largely unexplored therapeutic avenue in need of pursuit is a testament to the potential for T3D-959 to treat AD, a disease that we view as a chronic anorexia of the brain" said Chief Executive Officer  John Didsbury, Ph.D.  "We are truly honored by the support of the NIA and the confidence that our peers have shown in the science underpinning T3D-959."

"Given the enormous and growing impact of Alzheimer's on patients and families, there is an urgent need to develop and rigorously evaluate a larger and more diversified portfolio of promising late clinical stage treatments," said George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer's. "NIA's support of Phase 2 studies - including this study from  T3D Therapeutics - is to be commended and scaled if we are going to achieve our national goal of effectively treating Alzheimer's in the near future."

"NIA/NIH and its peer review system are to be lauded for supporting the logic of this new approach and excellent science of the T3D-959 program" said Robert Ingram, former Chief Executive Officer and Chairman of Glaxo/Wellcome.

Warren Strittmatter, M.D., Chief Medical Officer of T3D Therapeutics,  Emeritus Professor of Neurology at Duke University Medical Center and Alzheimer's Association Zenith Award winner said, "During my lengthy tenure treating AD patients I have seen firsthand the frustrations of caregivers and patients at the lack of an effective therapy with the plethora of recent drug development failures causing them to lose hope.  This award  provides great support for our promising new therapy to give them renewed optimism.  AD is being increasingly  recognized as  resulting from  abnormal brain metabolism.  T3D-959 is targeted toward  those metabolic pathways which appear  to  ultimately  produce amyloid plaques, tau tangles, inflammation and, most importantly, the  dementia."  

PIONEER is supported by the NIA under award number R01AG061122.

About T3D Therapeutics, Inc.

T3D Therapeutics, Inc. is a privately-held, Research Triangle Park, NC-based company. The Company has an exclusive license to T3D-959, its lead product candidate, and a platform of structurally-related molecules. T3D Therapeutics' mission is to develop and commercialize T3D-959 for the treatment of Alzheimer's disease and Mild Cognitive Impairment. T3D-959 is a small molecule, orally-delivered, brain-penetrating PPAR delta/gamma dual nuclear receptor agonist designed to improve glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders.

For more information visit http://www.t3dtherapeutics.com/.

Investor Contact

John Didsbury, Ph.D., CEO
T3D Therapeutics, Inc.
1-919-237-4897
Email: info (at) t3dtherapeutics (dot) com

More News by PR Newswire India

Third Annual Convocation Ceremony Will be Celebrated in Apex Professional University

An Encounter of Two Icons: Tic Tac® Meets Coca-Cola®

Birlasoft to Accelerate Invacare's Business Transformation Journey Signs US$ 240 mn, Multi-year Deal, to Provide Complete IT-as-a-Service (ITaaS)

Bali Zoo Celebrated Tumpek Kandang Ritual for all its Resident Faunas

Nitin Mantri Becomes ICCO President

DMCC Awarded 'Global Free Zone of the Year' for a Record Fifth Consecutive Year

Apex Professional University Signed MoU with Life Science Sector Skill Development Council

Find TVU Networks at Broadcast India 2019

UAE and UNESCO Renew Partnership, Extending Efforts to Restore Historic Churches in Mosul

Over 70,000 Visitors, SR2m Falcon Sales on First Day of Riyadh Exhibition

The First Huion Tablet of Inspiroy Dial Series, Q620M was Unveiled at Hong Kong Electronics Fair

ZEISS showcases next-level eye care digitalization at AAO 2019

On Your Marks: 2019 Xi'an Yango International Marathon Starts 20 October

Autodesk Fusion 360 Tools Enable Social Hardware to Advance Design of Prosthetics

Bionik Gold Knee- A New Lease of Life for Young Arthritis Patients

Joy Forum19 to boost Saudi entertainment sector

UAE and UNESCO Renew Partnership, Extending Efforts to Restore Historic Churches in Mosul

Over 70,000 Visitors, SR2m Falcon Sales on First Day of Riyadh Exhibition

The First Huion Tablet of Inspiroy Dial Series, Q620M was Unveiled at Hong Kong Electronics Fair

ZEISS showcases next-level eye care digitalization at AAO 2019

On Your Marks: 2019 Xi'an Yango International Marathon Starts 20 October

Autodesk Fusion 360 Tools Enable Social Hardware to Advance Design of Prosthetics

Bionik Gold Knee- A New Lease of Life for Young Arthritis Patients

Joy Forum19 to boost Saudi entertainment sector

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Earthquake felt in Bikaner, no casualtie...
Rahul Gandhi's involvement in state poll...
Ancient stories of brotherhood, Manipur ...
Telangana: Another RTC employee commits ...
Mangaluru's Apeksha Kottary enters India...
J-K: Postpaid mobile services to be func...
More...    
 
 Top Stories
UN chief condoles loss of lives by ... 
Taylor Swift, Antoni Porowski give ... 
Singapore adds Bangalore to its Glo... 
Maruti Suzuki collaborates with fiv... 
UP: 12 people dead in house collaps... 
Trudeau wears bulletproof vest for ... 
Morepen Labs adds three new drugs -... 
Acting is David Harbour's life...